A5063108609- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Organ and Tissue Transplantation Research
- Parathyroid Disorders and Treatments
- Organ Transplantation Techniques and Outcomes
- Medical Imaging and Pathology Studies
- Cardiac Valve Diseases and Treatments
- Viral Infections and Immunology Research
- Coronary Interventions and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- Pharmaceutical Economics and Policy
- Heparin-Induced Thrombocytopenia and Thrombosis
- Child and Adolescent Health
- Pneumocystis jirovecii pneumonia detection and treatment
- Pain Management and Treatment
- Cardiovascular Function and Risk Factors
- Cardiovascular Issues in Pregnancy
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Drug-Induced Adverse Reactions
- Pectus Deformity Diagnosis and Treatment
- Bone health and treatments
Cedars-Sinai Smidt Heart Institute
2012-2025
Cedars-Sinai Medical Center
2012-2025
University of California, San Francisco
2014-2019
The Stern Cardiovascular Foundation
2012
Recent studies suggest that cardiac amyloidosis (CA) is significantly underdiagnosed. For rare diseases like CA, the optimal selection of cases and controls for artificial intelligence model training unknown can impact performance.
Heart re-transplantation (re-HT) is the last treatment option for end-stage graft failure, with cases due to severe cardiac allograft vasculopathy (CAV) showing a better prognosis compared other indications. However, effects of restrictive physiology (RCP), classified as CAV, on re-HT outcomes remain unclear. We assessed patients CAV who underwent between 2010 and 2024. RCP was defined symptomatic heart failure echocardiographic values (E-to-A velocity ratio >2 deceleration time <150 ms) or...
Purpose. The most recent International Society for Heart and Lung Transplantation (ISHLT) biopsy scale classifies cellular antibody-mediated rejections. However, there are cases with acute decline in left ventricular ejection fraction (LVEF ≤ 45%) but no evidence of rejection on biopsy. Characteristics treatment response this negative (BNR) have yet to be elucidated. Methods. Between 2002 2012, we found 12 BNR 11 heart transplant patients as previously defined. One the was treated a second...
Heart transplant patients have risk factors that place them at higher for acute venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), than the general population. We assessed rate of VTE incidence PE-related mortality among heart patients.A total 1258 were evaluated development VTE. The diagnosis DVT was made by Duplex ultrasonography, PE diagnosed computerized tomography angiography or ventilation-perfusion radionuclide scan. one yr, three five...
While the revised UNOS HTx donor allocation system aimed to minimize waitlist mortality by prioritizing more critically ill transplant candidates, there is concern for increased post-transplant morbidity and mortality. We examined impact of on outcomes at a high-volume center.One hundred sixty nine adult patients underwent first-time single-organ one year before (Era 1:79 patients) after 2:90 implementation new (10/18/2018). Clinical characteristics, outcomes, were compared.Era 2 twice as...
Introduction: Despite the increased risk of sensitization in patients receiving pre-transplant durable mechanical circulatory support (D-MCS), it has been suggested that removing D-MCS at time transplant may lead to a drop HLA-antibody levels. Whether this reduce rejection rates and improve long-term outcomes undergoing heart-kidney transplantation (HKTx) not widely investigated. Therefore, we aim investigate impact on 5-year clinical HKTx. Methods: We included 98 HKTx between 2010 2018...
Background: Plasma donor-derived cell-free DNA (dd-cfDNA) has emerged as a biomarker for acute heart transplant rejection potential adjunct to endomyocardial biopsy (EMBx). However, an established threshold dd-cfDNA in cardiac is lacking, with prior studies employing different study specific thresholds. This meta-analysis aims assess the overall diagnostic accuracy of across various cutoffs and provide optimal threshold. Method: PubMed Web Science were searched relevant publications...
Introduction: Post-heart Transplant (HTx) ischemia-reperfusion injury (IRI) is associated with an increased risk of rejection and cardiac allograft vasculopathy (CAV). It has been suggested that induction therapy anti-thymocyte globulin (ATG) may protect against immediate (in the first 30 days) IRI post-HTx. Additionally, ATG reduced first-year coronary plaque progression as assessed by intravascular ultrasound (IVUS) among HTx recipients. Whether can decrease intimal thickening in patients...
Background: Microvascular dysfunction after heart transplantation leads to restrictive cardiac allograft physiology (RCP), which is classified severe coronary vasculopathy (CAV); however, the prognosis of RCP remains unclear. This study aimed elucidate in comparison with that angiographic CAV. Methods: We assessed patients defined as mean right atrial pressure >12 mmHg, pulmonary capillary wedge >25 and index <2.0 L/min/m 2 who underwent between 2004 2023. The primary outcome was...
Introduction: Post-heart Transplant (HTx) ischemia-reperfusion injury (IRI) is not uncommon and has been associated with an increased risk of rejection cardiac allograft vasculopathy. IRI may occur due to long ischemia time, high dose inotropes, technical surgical reasons. Identifying other recipient donor characteristics that might set patients at higher for developing help inform decision-making improve patient outcomes. Therefore, we aim investigate predictors immediately after HTx....
Background: After heart transplantation, endomyocardial biopsy (EMBx) is the standard diagnostic modality for acute rejection (AR). However, EMBx invasive with some limitations to conventional histological interpretation. Non-invasive assessments, such as cardiac magnetic resonance Imaging (MRI) and donor-derived cell-free DNA (dd-cfDNA) assays, have emerged viable methods diagnosing rejection. This study aims assess performance of MRI dd-cfDNA evaluating transplant Method PubMed Web Science...
ABSTRACT Background Diagnosis of cardiac amyloidosis (CA) is often missed or delayed due to confusion with other causes increased left ventricular wall thickness. Conventional transthoracic echocardiographic measurements like global longitudinal strain (GLS) has shown promise in distinguishing CA, but limited specificity. We conducted a study investigate the performance computer vision detection algorithm across multiple international sites. Methods EchoNet-LVH deep learning for based on...
Abstract Background Recent studies suggest that cardiac amyloidosis (CA) is significantly underdiagnosed. For rare diseases like CA, the optimal selection of cases and controls for artificial intelligence (AI) model training unknown can impact performance. Objectives This study evaluates performance ECG waveform-based AI models CA screening assesses different criteria defining controls. Methods Models were trained using including by ICD 9/10 code, amyloidosis, patients seen in clinic). The...